share_log

Johnson & Johnson | 8-K:Resolve of All Current and Future Ovarian Cancer Talc Claims

Johnson & Johnson | 8-K:Resolve of All Current and Future Ovarian Cancer Talc Claims

強生 | 8-K:解決所有當前和未來的卵巢癌滑石粉索賠方案
美股SEC公告 ·  09/21 04:22
牛牛AI助理已提取核心訊息
On September 20, 2024, Johnson & Johnson announced that its subsidiary, Red River Talc LLC, filed for a voluntary prepackaged Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of Texas. This strategic move aims to resolve all current and future ovarian cancer claims related to cosmetic talc litigation in the United States. The filing was supported by approximately 83% of the current claimants, surpassing the 75% approval threshold required by the U.S. Bankruptcy Code. After negotiations, Red River increased its settlement contribution by $1.75 billion, bringing the total to approximately $8 billion, to be paid over 25 years. This settlement is one of the largest in a mass tort bankruptcy case and offers claimants a better recovery than potential trial outcomes. Johnson & Johnson...Show More
On September 20, 2024, Johnson & Johnson announced that its subsidiary, Red River Talc LLC, filed for a voluntary prepackaged Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of Texas. This strategic move aims to resolve all current and future ovarian cancer claims related to cosmetic talc litigation in the United States. The filing was supported by approximately 83% of the current claimants, surpassing the 75% approval threshold required by the U.S. Bankruptcy Code. After negotiations, Red River increased its settlement contribution by $1.75 billion, bringing the total to approximately $8 billion, to be paid over 25 years. This settlement is one of the largest in a mass tort bankruptcy case and offers claimants a better recovery than potential trial outcomes. Johnson & Johnson has won approximately 95% of ovarian cases tried to date. The Plan also has the backing of the Future Claims Representative and will resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the U.S. The remaining 0.25% of lawsuits, related to mesothelioma, are being addressed separately. Johnson & Johnson maintains that the talc-related claims are without merit, citing decades of independent expert reviews and regulatory bodies' findings.
2024年9月20日,強生公司宣佈其子公司紅河滑石有限責任公司在美國德克薩斯州南區破產法院申請自願預打包第11章破產。此戰略舉措旨在解決與化妝品滑石訴訟有關的當前和未來所有卵巢癌索賠。申請得到了約83%的當前申請人的支持,超過美國破產法典規定的75%批准門檻。經過協商,紅河增加了其解決方案的貢獻額高達17.5億美元,總額約爲80億美元,將在25年內支付。這一和解是質量侵權破產案件中規模最大之一,爲申請人提供了比潛在審判結果更好的賠償。迄今爲止,強生公司已贏得約95%的卵巢案件。該計劃還得到了未來索賠代表的支持,並將解決針對強生公司及其關聯公司在美國的99.75%所有待定滑石訴訟。其餘0.25%的訴訟與間皮瘤有關,正在另行處理。強生公司堅稱滑石相關索賠毫無依據,援引數十年的獨立專家審查和監管機構的調查結果。
2024年9月20日,強生公司宣佈其子公司紅河滑石有限責任公司在美國德克薩斯州南區破產法院申請自願預打包第11章破產。此戰略舉措旨在解決與化妝品滑石訴訟有關的當前和未來所有卵巢癌索賠。申請得到了約83%的當前申請人的支持,超過美國破產法典規定的75%批准門檻。經過協商,紅河增加了其解決方案的貢獻額高達17.5億美元,總額約爲80億美元,將在25年內支付。這一和解是質量侵權破產案件中規模最大之一,爲申請人提供了比潛在審判結果更好的賠償。迄今爲止,強生公司已贏得約95%的卵巢案件。該計劃還得到了未來索賠代表的支持,並將解決針對強生公司及其關聯公司在美國的99.75%所有待定滑石訴訟。其餘0.25%的訴訟與間皮瘤有關,正在另行處理。強生公司堅稱滑石相關索賠毫無依據,援引數十年的獨立專家審查和監管機構的調查結果。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。